Cargando…
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy
BACKGROUND: Although programmed cell death 1 (PD‐1) blockade plus chemotherapy can significantly prolong the progression‐free survival (PFS) and overall survival (OS) in first‐line settings in patients with driver‐negative advanced non‐small‐cell lung cancer (NSCLC), the predictive biomarkers remain...
Autores principales: | Wu, Fengying, Jiang, Tao, Chen, Gongyan, Huang, Yunchao, Zhou, Jianying, Lin, Lizhu, Feng, Jifeng, Wang, Zhehai, Shu, Yongqian, Shi, Jianhua, Hu, Yi, Wang, Qiming, Cheng, Ying, Chen, Jianhua, Lin, Xiaoyan, Wang, Yongsheng, Huang, Jianan, Cui, Jiuwei, Cao, Lejie, Liu, Yunpeng, Zhang, Yiping, Pan, Yueyin, Zhao, Jun, Wang, LiPing, Chang, Jianhua, Chen, Qun, Ren, Xiubao, Zhang, Wei, Fan, Yun, He, Zhiyong, Fang, Jian, Gu, Kangsheng, Dong, Xiaorong, Zhang, Tao, Shi, Wei, Zou, Jianjun, Bai, Xuejuan, Ren, Shengxiang, Zhou, Caicun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759770/ https://www.ncbi.nlm.nih.gov/pubmed/36331328 http://dx.doi.org/10.1002/cac2.12383 |
Ejemplares similares
-
Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
por: Gao, Guanghui, et al.
Publicado: (2022) -
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
por: Jiang, Tao, et al.
Publicado: (2022) -
Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
por: Ren, Shengxiang, et al.
Publicado: (2022) -
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials
por: Mao, Shiqi, et al.
Publicado: (2023) -
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
por: Gao, Guanghui, et al.
Publicado: (2022)